For the prevention and management of uterine hemorrhage1

Methergine® is the Only
FDA-Approved Oral Uterotonic1,2

Methergine: The confidence of rapid control of blood loss due to uterine atony1

Methergine acts directly on the uterine smooth muscle, providing uterotonic efficacy to restrict blood loss1,3

  • Semi-synthetic ergot alkaloid therapeutic class3 – Ergot alkaloid derivatives have greater uterotonic than vasoconstrictive properties
  • Rapid onset of action—5-10 minutes after oral administration1 – Onset of action after IV administration is immediate; after IM administration, 2-5 minutes
Methergine 5-10 Minutes Onset of Action | FDA-Approved Oral Utertonic
Previous Next
The Knowledge Exchange | Help Fight Maternal Mortality

Help the
Knowledge Exchange in the
fight against maternal morbidity and mortality

  1. Methergine® (methylergonovine maleate) 0.2 mg Tablets Prescribing Information.
  2. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available at: http://www.accessdata.fda.gov/scripts/cderobdocs/tempai.cfm. Accessed March 4, 2016.
  3. de Groot AN, van Dongen PW, Vree TB, Hekster YA, van Roosmalen J. Ergot alkaloid. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs. 1998;56:523-535.